InvestorsObserver is giving Arbutus Biopharma Corp (ABUS) an Analyst Rating Rank of 69, meaning ABUS is ranked higher by analysts than 69% of stocks. The average projection by analysts for ABUS is $7 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
Analysts know the inner workings of the companies they follow better than anyone but the companies’ management. You can learn a lot about a company from studying the financial statements, but analysts ask questions on conference calls and understand the intricacies of each of the businesses they cover. Analysts understand how bad weather in one part of the world can disrupt supply chains, or disrupt shopping patterns. This lets traders make decisions before a quarterly report that could be worse than expected.
InvestorsObserver aggregates the ratings of all the analysts covering a given stock, takes the average of those ratings and then percentile ranks the averages. That provides a level of granularity that is significantly better than just the three levels provided by traditional buy/hold/sell ratings.
What's Happening With Arbutus Biopharma Corp Stock Today?
Arbutus Biopharma Corp (ABUS) stock is trading at $3.89 as of 3:40 PM on Thursday, Jan 7, a rise of $0.32, or 8.82% from the previous closing price of $3.57. The stock has traded between $3.60 and $4.06 so far today. Volume today is 4,462,491 compared to average volume of 4,862,977.